Since its discovery in the 1990s, "programmed cell death protein 1," or PD-1, has been regarded as a leading target in cancer treatments.

Cancer immunotherapy drugs called immune checkpoint inhibitors take the brakes off the body’s immune system, allowing it to ...

Discover the significance of C. elegans in biological research, from Nobel Prize-winning discoveries to insights into gene ...

Programmed cell death protein 1,” or PD-1, has been considered a key target in cancer therapies since its discovery in the ...

BCL-2 inhibitors, such as venetoclax (Venclexta) work by targeting the BCL-2 protein, which plays a key role in preventing ...

CYTO-102 is under clinical development by CytoImmune Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

The Food and Drug Administration has approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma.

A novel molecular tool developed by a Lehigh University professor of biological sciences is enabling scientists to precisely ...

Skin allergies are often worsened by psychological stress, but the underlying mechanisms remain poorly understood.

Much of our knowledge of the protein PD-1, a leading cancer treatment target, comes from studies in mice. In a comprehensive assessment of PD-1, researchers have found that PD-1 in mice is ...

Cadonilimab is under clinical development by Akeso and currently in Phase II for Metastatic Renal Cell Carcinoma.